285 related articles for article (PubMed ID: 8555226)
21. Engineering receptor-mediated cytotoxicity into human ribonucleases by steric blockade of inhibitor interaction.
Suzuki M; Saxena SK; Boix E; Prill RJ; Vasandani VM; Ladner JE; Sung C; Youle RJ
Nat Biotechnol; 1999 Mar; 17(3):265-70. PubMed ID: 10096294
[TBL] [Abstract][Full Text] [Related]
22. Improved yield and stability of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation, by protein engineering.
McDonagh CF; Beam KS; Wu GJ; Chen JH; Chace DF; Senter PD; Francisco JA
Bioconjug Chem; 2003; 14(5):860-9. PubMed ID: 13129388
[TBL] [Abstract][Full Text] [Related]
23. Crystallographic studies on structural features that determine the enzymatic specificity and potency of human angiogenin: Thr44, Thr80, and residues 38-41.
Holloway DE; Chavali GB; Hares MC; Baker MD; Subbarao GV; Shapiro R; Acharya KR
Biochemistry; 2004 Feb; 43(5):1230-41. PubMed ID: 14756559
[TBL] [Abstract][Full Text] [Related]
24. Role of the N terminus in RNase A homologues: differences in catalytic activity, ribonuclease inhibitor interaction and cytotoxicity.
Boix E; Wu Y; Vasandani VM; Saxena SK; Ardelt W; Ladner J; Youle RJ
J Mol Biol; 1996 Apr; 257(5):992-1007. PubMed ID: 8632481
[TBL] [Abstract][Full Text] [Related]
25. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain.
Masui H; Kamrath H; Apell G; Houston LL; Mendelsohn J
Cancer Res; 1989 Jul; 49(13):3482-8. PubMed ID: 2786451
[TBL] [Abstract][Full Text] [Related]
26. Molecular recognition of human angiogenin by placental ribonuclease inhibitor--an X-ray crystallographic study at 2.0 A resolution.
Papageorgiou AC; Shapiro R; Acharya KR
EMBO J; 1997 Sep; 16(17):5162-77. PubMed ID: 9311977
[TBL] [Abstract][Full Text] [Related]
27. The mouse angiogenin gene family: structures of an angiogenin-related protein gene and two pseudogenes.
Brown WE; Nobile V; Subramanian V; Shapiro R
Genomics; 1995 Sep; 29(1):200-6. PubMed ID: 8530072
[TBL] [Abstract][Full Text] [Related]
28. Isolation and characterization of angiogenin-1 and a novel protein designated lactogenin from bovine milk.
Ye XY; Cheng KJ; Ng TB
Biochem Biophys Res Commun; 1999 Sep; 263(1):187-91. PubMed ID: 10486275
[TBL] [Abstract][Full Text] [Related]
29. Characterization of single-chain antibody (sFv)-toxin fusion proteins produced in vitro in rabbit reticulocyte lysate.
Nicholls PJ; Johnson VG; Andrew SM; Hoogenboom HR; Raus JC; Youle RJ
J Biol Chem; 1993 Mar; 268(7):5302-8. PubMed ID: 8444903
[TBL] [Abstract][Full Text] [Related]
30. Single amino acid substitutions at the N-terminus of a recombinant cytotoxic ribonuclease markedly influence biochemical and biological properties.
Newton DL; Boque L; Wlodawer A; Huang CY; Rybak SM
Biochemistry; 1998 Apr; 37(15):5173-83. PubMed ID: 9548748
[TBL] [Abstract][Full Text] [Related]
31. Structural features that determine the enzymatic potency and specificity of human angiogenin: threonine-80 and residues 58-70 and 116-123.
Shapiro R
Biochemistry; 1998 May; 37(19):6847-56. PubMed ID: 9578571
[TBL] [Abstract][Full Text] [Related]
32. Unexpected binding mode for 2'-phosphoadenosine-based nucleotide inhibitors in complex with human angiogenin revealed by heteronuclear NMR spectroscopy.
Tonan K; Xu P; Jenkins JL; Russo A; Shapiro R; Ni F
Biochemistry; 2003 Sep; 42(38):11137-49. PubMed ID: 14503864
[TBL] [Abstract][Full Text] [Related]
33. High-level expression of three members of the murine angiogenin family in Escherichia coli and purification of the recombinant proteins.
Holloway DE; Hares MC; Shapiro R; Subramanian V; Acharya KR
Protein Expr Purif; 2001 Jul; 22(2):307-17. PubMed ID: 11437607
[TBL] [Abstract][Full Text] [Related]
34. Expression of the hAng gene in Escherichia coli; isolation and characterization of human recombinant Ser-(-1) angiogenin.
Lapidus AL; Mochul'skii AV; Podkovyrov SM; Lebedeva MI; Antipin AA; Izotova LS; Zagnit'ko OP; Komolova GS; Klesov AA; Veiko VP
Biomed Sci; 1990; 1(6):597-604. PubMed ID: 2132944
[TBL] [Abstract][Full Text] [Related]
35. Small cleavable adapters enhance the specific cytotoxicity of a humanized immunotoxin directed against CD64-positive cells.
Hetzel C; Bachran C; Fischer R; Fuchs H; Barth S; Stöcker M
J Immunother; 2008 May; 31(4):370-6. PubMed ID: 18391759
[TBL] [Abstract][Full Text] [Related]
36. Human placental ribonuclease inhibitor abolishes both angiogenic and ribonucleolytic activities of angiogenin.
Shapiro R; Vallee BL
Proc Natl Acad Sci U S A; 1987 Apr; 84(8):2238-41. PubMed ID: 3470787
[TBL] [Abstract][Full Text] [Related]
37. Fusion of the antiferritin antibody VL domain to barnase results in enhanced solubility and altered pH stability.
Martsev SP; Tsybovsky YI; Stremovskiy OA; Odintsov SG; Balandin TG; Arosio P; Kravchuk ZI; Deyev SM
Protein Eng Des Sel; 2004 Jan; 17(1):85-93. PubMed ID: 14985541
[TBL] [Abstract][Full Text] [Related]
38. Generation of active immunotoxins containing recombinant restrictocin.
Rathore D; Batra JK
Biochem Biophys Res Commun; 1996 May; 222(1):58-63. PubMed ID: 8630074
[TBL] [Abstract][Full Text] [Related]
39. Superadditive and subadditive effects of "hot spot" mutations within the interfaces of placental ribonuclease inhibitor with angiogenin and ribonuclease A.
Chen CZ; Shapiro R
Biochemistry; 1999 Jul; 38(29):9273-85. PubMed ID: 10413501
[TBL] [Abstract][Full Text] [Related]
40. A dimeric angiogenin immunofusion protein mediates selective toxicity toward CD22+ tumor cells.
Arndt MA; Krauss J; Vu BK; Newton DL; Rybak SM
J Immunother; 2005; 28(3):245-51. PubMed ID: 15838381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
